Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05099263 · ClinicalTrials.gov registry record · NA

The Vivaer Procedure for Treatment of the Septal Swell Bodies (SWELL)

A NA study, sponsored by Aerin Medical.

Completed
Registry status
NA
Development phase
70
Enrollment target

NCT05099263: Completed NA study, sponsored by Aerin Medical.

NCT05099263 is a NA study that has completed, run by Aerin Medical. The registered enrollment target is 70 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05099263, a NA study, has completed, sponsored by Aerin Medical.

COMPLETED
Registry status
NA
Development phase
70 participants
Enrollment target

Study Summary

Post-market study to access the clinical use of the Vivaer Arc Stylus to treat Septal Swell Bodies (SSB).

Primary Outcome

The primary endpoint is improvement in self-reported Nasal Obstruction Symptom Evaluation (NOSE) Scale score from baseline recorded at the screening evaluation to 13 weeks after the procedure. The NOSE Scale is a validated disease-specific health status instrument used by clinicians to measure the outcome of participants treated for nasal obstruction.43 The NOSE Scale consists of 5 items, each scored using a 5-point Likert scale to make a total score range of 0 through 100, where higher scores i

Interventions

  • DEVICE Vivaer Arc Stylus

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2021-09-14
Est. Completion 2024-10-16
Phase NA
Aerin Medical

14 total trials

What the finished NCT05099263 record still lists

NCT05099263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 1 intervention - of which Vivaer Arc Stylus is the first listed.

NCT05099263 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05099263 about?

NCT05099263 is a clinical study titled "The Vivaer Procedure for Treatment of the Septal Swell Bodies (SWELL)". Post-market study to access the clinical use of the Vivaer Arc Stylus to treat Septal Swell Bodies (SSB).

What is the current status of trial NCT05099263?

This trial is currently completed. It is a NA study. The enrollment target is 70 participants. The study started on 2021-09-14. Estimated completion is 2024-10-16.

What interventions are being tested in trial NCT05099263?

The interventions under investigation include: Vivaer Arc Stylus (DEVICE).

Who is sponsoring clinical trial NCT05099263?

This trial is sponsored by Aerin Medical, which has 14 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05099263's enrollment target sits among peer trials

70 1103rd of 2000 higher than 868 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00969111 · 70 participants · NA

    Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

  • NCT01712620 · 70 participants · Phase 2

    Spironolactone for Pulmonary Arterial Hypertension

  • NCT02143830 · 70 participants · Phase 2

    HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

  • NCT02601339 · 70 participants

    NIRS Monitoring in Premature Infants

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05099263, the US trial registry maintained by the National Library of Medicine. NCT05099263 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.